Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Ocrelizumab (Ocrevus; Genentech Inc.) for primary progressive and relapsing-remitting multiple sclerosis. Lansdale: HAYES, Inc. Healthcare Technology Brief Publication. 2017 Authors' conclusions Multiple sclerosis (MS) is an autoimmune disorder that impacts the spinal cord and brain. MS presents in various forms, including relapsing-remitting MS (RRMS) or primary progressive MS (PPMS). Technology Description:
Ocrelizumab (Ocrevus) is a humanized monoclonal antibody therapy that is directed toward cluster of differentiation (CD)20, which is a B-cell surface molecule. Ocrelizumab exerts its immunomodulatory effect by selectively depleting CD20-expressing B cells, which may provide therapeutic benefit in immune disorders such as RRMS and PPMS.
Clinical Alternatives:
There are several alternative disease-modifying therapies for MS, including beta
interferons, glatiramer acetate, fingolimod, and natalizumab. Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal, Humanized; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; ocrelizumab Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: hayesinfo@hayesinc.com AccessionNumber 32018000075 Date abstract record published 14/02/2018 |